$182.2 Million

Rapid Micro Biosystems, Inc.

Initial Public Offering

Bookrunner, July 2021

Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc. (the “Company”) is an innovative bioprocessing company providing mission-critical automation solutions to its customers to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s Growth Direct® platform automates and modernizes the manual microbial quality control testing workflows used by the largest and most complex pharmaceutical manufacturers. The Growth Direct platform delivers faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that the Company’s customers rely on to ensure a safe and consistent supply of their products.